A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Revolution Medicines, Inc.
GlaxoSmithKline
Accent Therapeutics
A2 Biotherapeutics Inc.
Revolution Medicines, Inc.
GlaxoSmithKline
Natera, Inc.
Novartis
Massive Bio, Inc.
Elicio Therapeutics
Guardant Health, Inc.
ModeX Therapeutics, An OPKO Health Company
Tempus AI
Taproot Health
DxTerity Diagnostics
UTC Therapeutics Inc.
Corvus Pharmaceuticals, Inc.
Klus Pharma Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
MacroGenics
Stryker Orthopaedics
SpeciCare
SPGO Research Mannheim GmbH
INSYS Therapeutics Inc
Siemens Molecular Imaging
Light Sciences LLC